German VC firm Peppermint Venture Partners has led a €800,000 in vaccine developer CAP-CMV.
The investment was made via the new Charité Biomedical Fund, with additional financing was provided by NRW.Bank, Creathor Venture, KfW and private investors.
CAP-CMV is developing a novel vaccine protecting against human Cytomegalovirus (HCMV) infection.
The capital will be used to advance CAP-CMV’s novel vaccine candidate, protecting against human Cytomegalovirus (HCMV) infection. The company was established as a joint project between CEVEC Pharmaceuticals, Vakzine Projekt Management GmbH (VPM) and Professor Plachter of the University Medical Center Mainz in 2013.
Joachim Rautter, managing partner at PVP, said, “To date nearly all approaches to develop a potent vaccine against HCMV infection failed because of insufficient immune responses or poor efficacy. CAP-CMV aims to solve this unmet medical need by using its DB-based vaccine first in solid-organ transplantation patients and will later address congenital HCMV infections. This makes it a very attractive investment opportunity and we are very much looking forward to work with an experienced and professional team to assure the success of this unique development programme.”
Wolfgang Kintzel, CEO, CAP-CMV added, “The funds will enable us to advance our novel DB vaccine approach to treat and prevent HCMV infections and it provides the basis for a larger financing round in 2014 to advance our program into the clinical development stage.”
Berlin-based Peppermint invests in healthcare companies with a focus on medical devices and selected pharmaceutical projects, mainly within Europe. At the end of 2010 PVP in association with the Charité Foundation launched the new Charité Biomedical Fund withinn the framework of its established collaboration with medical school the Charité – Universitätsmedizin Berlin.
Copyright © 2013 AltAssets